Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians

被引：31

作者：

Principe, Luigi ^{[1
]}

Lupia, Tommaso ^{[2
]}

Andriani, Lilia ^{[3
]}

Campanile, Floriana ^{[4
]}

Carcione, Davide ^{[5
]}

Corcione, Silvia ^{[6
]}

De Rosa, Francesco Giuseppe ^{[2
]}

Luzzati, Roberto ^{[7
]}

Stroffolini, Giacomo ^{[6
]}

Steyde, Marina ^{[7
]}

Decorti, Giuliana ^{[7
,8
]}

Di Bella, Stefano ^{[7
]}

机构：

[1] San Giovanni Dio Hosp, Clin Pathol & Microbiol Unit, I-88900 Crotone, Italy

[2] Cardinal Massaia Hosp, Infect Dis Unit, I-14100 Asti, Italy

[3] Hosp Sondrio, Clin Pathol & Microbiol Unit, I-23100 Sondrio, Italy

[4] Univ Catania, Microbiol Sect, Dept Biomed & Biotechnol Sci, I-95123 Catania, Italy

[5] IRCCS San Raffaele Sci Inst, Lab Microbiol & Virol, I-20132 Milan, Italy

[6] Univ Torino, Dept Med Sci, Infect Dis Unit, I-10124 Turin, Italy

[7] Univ Trieste, Dept Clin Med, Surg & Hlth Sci, I-34149 Trieste, Italy

[8] IRCCS Burlo Garofolo, Inst Maternal & Child Hlth, I-34137 Trieste, Italy

来源：

PHARMACEUTICALS | 2022年 / 15卷 / 04期

关键词：

beta-lactams; beta-lactamase inhibitors; cefiderocol; pharmacokinetics; pharmacodynamics; URINARY-TRACT-INFECTIONS; COMPLICATED INTRAABDOMINAL INFECTIONS; EPITHELIAL LINING FLUID; DOUBLE-BLIND; PSEUDOMONAS-AERUGINOSA; CEFTAZIDIME-AVIBACTAM; MEROPENEM-VABORBACTAM; PLUS METRONIDAZOLE; SAFETY; CEFTOLOZANE/TAZOBACTAM;

D O I：

10.3390/ph15040463

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Bacterial resistance mechanisms are continuously and rapidly evolving. This is particularly true for Gram-negative bacteria. Over the last decade, the strategy to develop new beta-lactam/beta-lactamase inhibitors (BLs/BLIs) combinations has paid off and results from phase 3 and real-world studies are becoming available for several compounds. Cefiderocol warrants a separate discussion for its peculiar mechanism of action. Considering the complexity of summarizing and integrating the emerging literature data of clinical outcomes, microbiological mechanisms, and pharmacokinetic/pharmacodynamic properties of the new BL/BLI and cefiderocol, we aimed to provide an overview of data on the following compounds: aztreonam/avibactam, cefepime/enmetazobactam, cefepime/taniborbactam, cefepime/zidebactam, cefiderocol, ceftaroline/avibactam, ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/relebactam, meropenem/nacubactam and meropenem/vaborbactam. Each compound is described in a dedicated section by experts in infectious diseases, microbiology, and pharmacology, with tables providing at-a-glance information.

引用

页数：25

共 154 条

[1] In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria [J].

Abdelraouf, Kamilia ;

Abuhussain, Safa Almarzoky ;

Nicolau, David P. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (12) :3601-3610

[2] Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections [J].

Ackley, Renee ;

Roshdy, Danya ;

Meredith, Jacqueline ;

Minor, Sarah ;

Anderson, William E. ;

Capraro, Gerald A. ;

Polk, Christopher .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (05)

[3] Successful treatment of infective endocarditis due to pandrug-resistant Klebsiella pneumoniae with ceftazidime-avibactam and aztreonam [J].

Alghoribi, Majed F. ;

Alqurashi, Moayad ;

Okdah, Liliane ;

Alalwan, Bassam ;

AlHebaishi, Yahya S. ;

Almalki, Abdulmajeed ;

Alzayer, Maha A. ;

Alswaji, Abdulrahman A. ;

Doumith, Michel ;

Barry, Mazin .

SCIENTIFIC REPORTS, 2021, 11 (01)

[4] Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections [J].

Alosaimy, Sara ;

Jorgensen, Sarah C. J. ;

Lagnf, Abdalhamid M. ;

Melvin, Sarah ;

Mynatt, Ryan P. ;

Carlson, Travis J. ;

Garey, Kevin W. ;

Allen, David ;

Venugopalan, Veena ;

Veve, Michael ;

Athans, Vasilios ;

Saw, Stephen ;

Yost, Christine N. ;

Davis, Susan L. ;

Rybak, Michael J. .

OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (03)

[5] Ceftolozane/Tazobactam in Neonates and Young Infants: The Challenges of Collecting Pharmacokinetics and Safety Data in This Vulnerable Patient Population [J].

Ang, Jocelyn Y. ;

Arrieta, Antonio ;

Bradley, John S. ;

Zhang, Zufei ;

Yu, Brian ;

Rizk, Matthew L. ;

Johnson, Matthew G. ;

Rhee, Elizabeth G. .

AMERICAN JOURNAL OF PERINATOLOGY, 2021, 38 (08) :804-809

[6] Meropenem-nacubactam activity against AmpC-overproducing and KPC-expressing Pseudomonas aeruginosa in a neutropenic murine lung infection model [J].

Asempa, Tomefa E. ;

Motos, Ana ;

Abdelraouf, Kamilia ;

Bissantz, Caterina ;

Zampaloni, Claudia ;

Nicolau, David P. .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (02)

[7] Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant Klebsiella pneumoniae Bacteremia and Abscess in a Liver Transplant Recipient [J].

Athans, Vasilios ;

Neuner, Elizabeth A. ;

Hassouna, Habiba ;

Richter, Sandra S. ;

Keller, George ;

Castanheira, Mariana ;

Brizendine, Kyle D. ;

Mathers, Amy J. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (01)

[8] Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC [J].

Barnes, Melissa D. ;

Taracila, Magdalena A. ;

Good, Caryn E. ;

Bajaksouzian, Saralee ;

Rojas, Laura J. ;

van Duin, David ;

Kreiswirth, Barry N. ;

Jacobs, Michael R. ;

Haldimann, Andreas ;

Papp-Wallace, Krisztina M. ;

Bonomo, Robert A. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (08)

[9] Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial [J].

Bassetti, Matteo ;

Echols, Roger ;

Matsunaga, Yuko ;

Ariyasu, Mari ;

Doi, Yohei ;

Ferrer, Ricard ;

Lodise, Thomas P. ;

Naas, Thierry ;

Niki, Yoshihito ;

Paterson, David L. ;

Portsmouth, Simon ;

Torre-Cisneros, Julian ;

Toyoizumi, Kiichiro ;

Wunderink, Richard G. ;

Nagata, Tsutae D. .

LANCET INFECTIOUS DISEASES, 2021, 21 (02) :226-240

[10] Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience [J].

Bassetti, Matteo ;

Castaldo, Nadia ;

Cattelan, Annamaria ;

Mussini, Cristina ;

Righi, Elda ;

Tascini, Carlo ;

Menichetti, Francesco ;

Mastroianni, Claudio Maria ;

Tumbarello, Mario ;

Grossi, Paolo ;

Artioli, Stefania ;

Carannante, Novella ;

Cipriani, Ludovica ;

Coletto, Davide ;

Russo, Alessandro ;

Digaetano, Margherita ;

Losito, Angela Raffaella ;

Peghin, Maddalena ;

Capone, Alessandro ;

Nicole, Stefano ;

Vena, Antonio ;

Pecori, Davide ;

Carnellutti, Alessia ;

Givone, Filippo ;

Graziano, Elena ;

Merelli, Maria ;

Cadeo, Barbara ;

Verdenelli, Stefano ;

Fabiani, Silvia ;

Gianluca, Russo ;

Oliva, Alessandra ;

Ciardi, Maria Rosa ;

Ajassa, Camilla ;

Tieghi, Tiziana ;

Tumbarello, Mario ;

Raffaelli, Francesca ;

Rovelli, Cristina ;

Caruana, Giorgia ;

Luzzati, Roberto ;

Bontempo, Giulia ;

Petrosillo, Nicola ;

Rizzardini, Giuliano ;

Coen, Massimo ;

Passerini, Matteo ;

Mastroianni, Antonio ;

Urso, Filippo ;

Bianco, Maria Francesca ;

Borgia, Guglielmo ;

Gentile, Ivan ;

Maraolo, Alberto Enrico .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 53 (04) :408-415

← 1 2 3 4 5 6 7 8 9 10 →